Educate policymakers on the industry to avoid bad or over-simplified healthcare reform legislation.
In the short term, as reform legislation is being crafted, the healthcare industry would be best served by educating policymakers and, hopefully, would avoid bad legislation, according to a Milliman healthcare reform briefing paper.
“Looking forward into the post-reform world, execs will need to be prepared for the possibility of a different-possibly dramatically different-landscape,” says Thomas D. Snook, FSA, MAAA, principal and consulting actuary, Milliman. “All of us will need to be agile and flexible to adapt to new market conditions and perhaps give up old maxims. Evolve or prepare for extinction.”
The paper provides a primer on certain key variables that influence the cost of healthcare-and thus health insurance-in complex ways.
“Our primary intended audience is those outside the managed care/health insurance industry,” Snook says. “These individuals may not intuitively grasp some of these ideas, which those of us in the industry have dealt with for years and hence are intimately familiar with. Our goal is to caution those in a position to reform healthcare that the issues are very complex and will not be easily solved with a simplistic approach.”
Any reform legislation that does not adequately take these considerations into account will probably fail to meet its goals and may be counterproductive, according to Snook.
The primary focus of the paper is benefit design issues.
“We attempt to highlight commonalities and differences in plan designs present in the marketplace today, with an explanation of why the designs look and function like they do,” Snook explains. “We also address variability in cost due to geographic differences and provider reimbursement levels and note that all these factors interact in complex ways.”
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More